Prospective Study
Copyright ©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jun 14, 2017; 23(22): 4102-4111
Published online Jun 14, 2017. doi: 10.3748/wjg.v23.i22.4102
Drug-induced liver injury in inflammatory bowel disease: 1-year prospective observational study
Tomas Koller, Martina Galambosova, Simona Filakovska, Michaela Kubincova, Tibor Hlavaty, Jozef Toth, Anna Krajcovicova, Juraj Payer
Tomas Koller, Martina Galambosova, Simona Filakovska, Michaela Kubincova, Tibor Hlavaty, Jozef Toth, Anna Krajcovicova, Juraj Payer, 5th Department of Internal Medicine, Gastroenterology and Hepatology, Comenius University in Bratislava Faculty of Medicine, University Hospital Bratislava Ruzinov, 82606 Bratislava, Slovakia
Author contributions: Koller T drafted the manuscript, designed the protocol and performed data analysis; Galambosova M supervised and participated in data collection; Filakovska S participated in data collection; Kubincova M participated in data collection; Hlavaty T revised the protocol design, assisted with data analysis, participated in patient clinical management; Toth J participated in patient clinical management; Krajcovicova A participated in data collection and assisted at data analysis; Payer J suggested the subject of the study and participated at the discussion, approved the final manuscript.
Institutional review board statement: The study was reviewed and approved by the institutional ethics committee board of the University Hospital Bratislava Ruzinov of Slovakia.
Clinical trial registration statement: This study did not include any intervention or patient randomization, therefore clinical trial registration was not done.
Informed consent statement: All study participants, or their legal guardian, provided written informed consent prior to any diagnostic or therapeutic procedure. Informed consent for patient data collection was not required by the institutional ethics committee.
Conflict-of-interest statement: The authors of the manuscript having no conflicts of interest to disclose.
Data sharing statement: There is no additional data available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Tomas Koller, MD, PhD, Associate Professor, 5th Department of Internal Medicine, Gastroenterology and Hepatology, Comenius University in Bratislava Faculty of Medicine, University Hospital Bratislava Ruzinov, Ruzinovska 6, 82606 Bratislava, Slovakia. tomas.koller@ru.unb.sk
Telephone: +42-190-5118692 Fax: +42-190-5118692
Received: January 28, 2017
Peer-review started: February 8, 2017
First decision: March 16, 2017
Revised: March 29, 2017
Accepted: May 9, 2017
Article in press: May 9, 2017
Published online: June 14, 2017
Core Tip

Core tip: We evaluated liver injury in consecutive inflammatory bowel disease (IBD) patients followed for one year in whom aminotransferase activities (AT) were measured at baseline and at 3 mo intervals. We found AT elevations frequently, but they were mostly mild and transient. Even persisting abnormalities had rarely an effect on IBD management. However, ALT elevations and cholestasis appeared more commonly among patients treated with infliximab (ALT) or azathioprine (cholestasis). This finding points to their potential for hepatotoxicity and the need for regular AT monitoring.